Thank you very much;
you're only a step away from
downloading your reports.
Stocks: Insiders Buy at Opko Health and Synageva BioPharma, Sell at EXCO Resources
Plus, a purchase at NxStage Medical.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:

  • Felix Baker, Chairman of clinical-stage biopharmaceutical company Synageva BioPharma (NASDAQ:GEVA), bought 375,000 shares of company stock for $39,656,248.
  • Phillip Frost, Chairman and CEO of multinational diagnostics and biopharmaceutical company Opko Health (NYSE:OPK), bought 41,500 shares of company stock for $379,532.
  • Robert Funari, a director at medical device company NxStage Medical (NASDAQ:NXTM), bought 10,150 shares of company stock for $149,408.

Notable Sale:

  • American business magnate and financier T. Boone Pickens, a director at independent oil and natural gas company EXCO Resources (NYSE:XCO), sold 2,269,100 shares of company stock for $11,738,028.

For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
DIR,BO
B
$39,656,248
2
DIR,BO
B
$15,000,006
3
BO
B
$3,191,045
4
VP,CFO
B
$547,651
5
DIR
JB*
$402,500
6
CEO,CB,BO
B
$379,532
7
DIR
JB*
$349,968
8
FO,DIR,BO
JB*
$316,676
9
DIR
B
$149,408
10
BO
B
$126,913

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
S
$44,317,365
2
DIR
S
$11,738,028
3
BO
S
$8,082,200
4
DIR,BO
S
$8,065,459
5
DIR,BO
S
$7,622,635
6
VP,GC
S,JS*
$6,861,110
7
DIR
S
$5,877,986
8
VP
AS
$4,429,664
9
DIR
S
$2,791,691
10
BO
S
$2,604,850

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
Stocks: Insiders Buy at Opko Health and Synageva BioPharma, Sell at EXCO Resources
Plus, a purchase at NxStage Medical.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:

  • Felix Baker, Chairman of clinical-stage biopharmaceutical company Synageva BioPharma (NASDAQ:GEVA), bought 375,000 shares of company stock for $39,656,248.
  • Phillip Frost, Chairman and CEO of multinational diagnostics and biopharmaceutical company Opko Health (NYSE:OPK), bought 41,500 shares of company stock for $379,532.
  • Robert Funari, a director at medical device company NxStage Medical (NASDAQ:NXTM), bought 10,150 shares of company stock for $149,408.

Notable Sale:

  • American business magnate and financier T. Boone Pickens, a director at independent oil and natural gas company EXCO Resources (NYSE:XCO), sold 2,269,100 shares of company stock for $11,738,028.

For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
DIR,BO
B
$39,656,248
2
DIR,BO
B
$15,000,006
3
BO
B
$3,191,045
4
VP,CFO
B
$547,651
5
DIR
JB*
$402,500
6
CEO,CB,BO
B
$379,532
7
DIR
JB*
$349,968
8
FO,DIR,BO
JB*
$316,676
9
DIR
B
$149,408
10
BO
B
$126,913

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
S
$44,317,365
2
DIR
S
$11,738,028
3
BO
S
$8,082,200
4
DIR,BO
S
$8,065,459
5
DIR,BO
S
$7,622,635
6
VP,GC
S,JS*
$6,861,110
7
DIR
S
$5,877,986
8
VP
AS
$4,429,664
9
DIR
S
$2,791,691
10
BO
S
$2,604,850

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
Stocks: Insiders Buy at Opko Health and Synageva BioPharma, Sell at EXCO Resources
Plus, a purchase at NxStage Medical.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:

  • Felix Baker, Chairman of clinical-stage biopharmaceutical company Synageva BioPharma (NASDAQ:GEVA), bought 375,000 shares of company stock for $39,656,248.
  • Phillip Frost, Chairman and CEO of multinational diagnostics and biopharmaceutical company Opko Health (NYSE:OPK), bought 41,500 shares of company stock for $379,532.
  • Robert Funari, a director at medical device company NxStage Medical (NASDAQ:NXTM), bought 10,150 shares of company stock for $149,408.

Notable Sale:

  • American business magnate and financier T. Boone Pickens, a director at independent oil and natural gas company EXCO Resources (NYSE:XCO), sold 2,269,100 shares of company stock for $11,738,028.

For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
DIR,BO
B
$39,656,248
2
DIR,BO
B
$15,000,006
3
BO
B
$3,191,045
4
VP,CFO
B
$547,651
5
DIR
JB*
$402,500
6
CEO,CB,BO
B
$379,532
7
DIR
JB*
$349,968
8
FO,DIR,BO
JB*
$316,676
9
DIR
B
$149,408
10
BO
B
$126,913

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
S
$44,317,365
2
DIR
S
$11,738,028
3
BO
S
$8,082,200
4
DIR,BO
S
$8,065,459
5
DIR,BO
S
$7,622,635
6
VP,GC
S,JS*
$6,861,110
7
DIR
S
$5,877,986
8
VP
AS
$4,429,664
9
DIR
S
$2,791,691
10
BO
S
$2,604,850

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
EDITOR'S PICKS
 
WHAT'S POPULAR